KalVista Pharma to Present Six Abstracts at 2024 Bradykinin Symposium

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the acceptance of multiple abstracts for presentation at the 2024 Bradykinin Symposium in Berlin, Germany, scheduled for September 5-6, 2024. The presentations will provide significant insights into the treatment of Hereditary Angioedema (HAE) and will cover various studies and analyses related to the company's therapies.

On September 6, several oral presentations will be held in the Kaiserin Friedrich-Haus Lecture Hall. Among them, Mauro Cancian and colleagues will present findings on the delayed on-demand treatment of HAE attacks, highlighting barriers reported by Italian patients. This session will take place from 9:20 to 9:30 CET. Following this, from 9:30 to 9:40 CET, Emel Aygören-Pürsün and associates will discuss the pooled placebo-controlled safety data for sebetralstat, an on-demand treatment for HAE.

Later in the day, Session V will feature a presentation by D. Lee and team from 11:50 to 12:00 CET, focusing on a specific sensitivity assay measuring plasma kallikrein activity in patient samples. This assay is critical for understanding the biochemical dynamics in HAE patients and tailoring effective treatments.

In the afternoon, from 13:10 to 13:20 CET, Henriette Farkas and her colleagues will share an interim analysis from the KONFIDENT-S trial, which evaluates sebetralstat for treating HAE attacks, including those affecting the larynx. This presentation is part of Session VI.

In addition to oral presentations, the symposium will also feature poster presentations. Among the highlighted posters is a study on the pooled placebo-controlled efficacy of sebetralstat for on-demand HAE treatment, presented by Marcus Maurer and his research team. This session is scheduled for 15:35 to 16:15 CET. Another poster presentation, also taking place from 15:35 to 16:15 CET, will cover the Phase 3 KONFIDENT trial of sebetralstat, focusing on the European subgroup. This research involves a collaborative effort among several prominent researchers, including Andrea Zanichelli and Henriette Farkas.

KalVista Pharmaceuticals is a global company dedicated to developing and delivering oral medicines for diseases with significant unmet needs. Earlier this year, KalVista reported positive phase 3 results from the KONFIDENT trial for sebetralstat, its oral, on-demand therapy for HAE. The company has since filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in June 2024 and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in August 2024. Plans are also underway to seek approval in the UK, Japan, and other regions later in the year.

The presentations at the Bradykinin Symposium reflect KalVista's ongoing commitment to advancing the treatment of HAE and other related conditions. The data shared will offer valuable insights into the efficacy, safety, and biochemical mechanisms of sebetralstat, potentially paving the way for improved patient outcomes and broader therapeutic options.

KalVista's proactive approach in sharing their research findings at international forums underscores their leadership in the pharmaceutical industry, particularly in the area of HAE treatment. The symposium will serve as an important platform for the exchange of knowledge and the exploration of new frontiers in managing this debilitating condition.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!